Advertisement
Singapore markets closed

  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     

  • S&P 500

    5,011.18
    -60.45 (-1.19%)
     

  • Dow

    37,867.60
    -593.32 (-1.54%)
     

  • Nasdaq

    15,462.17
    -250.58 (-1.59%)
     

  • Bitcoin USD

    63,641.88
    -1,200.45 (-1.85%)
     

  • CMC Crypto 200

    1,374.28
    -8.30 (-0.60%)
     

  • FTSE 100

    8,076.01
    +35.63 (+0.44%)
     

  • Gold

    2,343.30
    +4.90 (+0.21%)
     

  • Crude Oil

    82.33
    -0.48 (-0.58%)
     

  • 10-Yr Bond

    4.7080
    +0.0560 (+1.20%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Company News For Sep 30, 2019

Zacks Equity Research

  • Wells Fargo & Co.’s WFC shares surged 3.8% after the company appointed Charles Scharf as chief executive officer, which was vacant for past six months.

  • Pfizer Inc. PFE gained 1.2% following favorable results in a second late-stage trial of its drug for moderate to severe atopic dermatitis.

  • LATAM Airlines Group S.A. LTM shares jumped 31.1% after Delta Air Lines Inc. DAL agreed to acquire 20% stake of the company for $1.9 billion.

  • Shares of Las Vegas Sands Corp. LVS climbed 2.2% following news that the company will enter the benchmark S&P 500 Index on Oct 3 replacing Nektar Therapeutics NKTR.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Delta Air Lines, Inc. (DAL) : Free Stock Analysis Report
 
Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report
 
Wells Fargo & Company (WFC) : Free Stock Analysis Report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
LATAM Airlines Group S.A. (LTM) : Free Stock Analysis Report
 
Nektar Therapeutics (NKTR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research